• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by CRISPR Therapeutics AG

    6/5/26 8:15:06 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRSP alert in real time by email
    S-8 1 crsp-20260605.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 5, 2026

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    CRISPR THERAPEUTICS AG

    (Exact name of registrant as specified in its charter)

     

     

    Switzerland

    Not applicable

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

     

    Baarerstrasse 14

    6300 Zug

    Switzerland

    +41 (0)41 561 32 79

    (Address of principal executive offices)

    Not Applicable

    (Zip Code)

    CRISPR Therapeutics AG

    2026 Stock Option and Incentive Plan

    (Full title of the plan)

    Samarth Kulkarni, Ph.D.

    Chief Executive Officer

    c/o CRISPR Therapeutics, Inc.

    105 West First Street

    South Boston, MA 02127

    (Name and address of agent for service)

     

    617-315-4600

    (Telephone number, including area code, of agent for service)

    Copies to:

     

     

    Robert E. Puopolo

    Marishka DeToy

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, MA 02210

    (617) 570-1000

    James R. Kasinger
    General Counsel and Secretary
    CRISPR Therapeutics AG
    Baarerstrasse 14

    6300 Zug

    Switzerland

    +41 (0)41 561 32 79

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☒

    Accelerated filer

    ☐

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☐

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐


    Part I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1. Plan Information.

    The documents containing the information specified in this Item 1 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement on Form S-8 (“Registration Statement”) or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

    Item 2. Registrant Information and Employee Plan Annual Information.

    The documents containing the information specified in this Item 2 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The registrant hereby incorporates by reference into this Registration Statement the following documents filed with the Commission:

    (a) The Annual Report on Form 10-K filed by the registrant for the year ended December 31, 2025, filed with the Commission on February 12, 2026 (including those portions of the Definitive Proxy Statement for the registrant’s 2026 Annual General Meeting of Shareholders incorporated by reference therein);

    (b) The Quarterly Report on Form 10-Q filed by the registrant for the quarter ended March 31, 2026, filed with the Commission on May 4, 2026;

    (c) The Current Reports on Form 8-K filed by the registrant with the Commission on January 12, 2026, March 11, 2026, March 16, 2026 and June 4, 2026; and

    (d) The description of the registrant’s common shares contained in the registrant’s Registration Statement on Form 8-A (File No. 001-37923), filed by the registrant with the Commission under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on October 18, 2016, including any amendments or reports filed for the purpose of updating such description.

    All documents that the registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the common shares offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Under no circumstances will any information filed under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.


    Under Swiss law, a corporation may indemnify its directors or officers against losses and expenses (except for such losses and expenses arising from willful misconduct or negligence, although legal scholars advocate that at least gross negligence be required), including attorney’s fees, judgments, fines and settlement amounts actually and reasonably incurred in a civil or criminal action, suit or proceeding by reason of having been the representative of, or serving at the request of, the corporation.

    Subject to Swiss law, Article 29 of the registrant’s articles of association provides for indemnification of the existing and former members of the registrant’s board of directors, executive management, and their heirs, executors and administrators, against liabilities arising in connection with the performance of their duties in such capacity, and permits the registrant to advance the expenses of defending any act, suit or proceeding to members of our board of directors and executive management, provided the member concerned undertakes to repay such amounts in case it is ultimately not entitled to indemnification under the registrant’s articles of association, provided the member concerned undertakes to repay such amounts in case it is ultimately not entitled to indemnification under the registrant’s articles of association.

    In addition, under general principles of Swiss employment law, an employer may be required to indemnify an employee against losses and expenses incurred by such employee in the proper execution of their duties under the employment agreement with the company.

    The registrant has entered into indemnification agreements with each of its members of the board of directors and executive officers.

    The registrant has purchased and maintains insurance on behalf of any person who is or was a director or officer against any loss arising from any claim asserted against him or her and incurred by him or her in that capacity, subject to certain exclusions and limits of the amount of coverage.

    These indemnification provisions and the indemnification agreements entered into between the registrant and its officers and directors may be sufficiently broad to permit indemnification of the registrant’s officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    Exhibit
    Number

     

    Description

     

      4.1

     

    Amended and Restated Articles of Association (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 4, 2026).

     

      5.1*

     

    Opinion of Walder Wyss AG, Swiss counsel of the Registrant, as to the validity of the common shares.

     

    23.1*

     

    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.

     

    23.2*

     

    Consent of Walder Wyss AG (included in Exhibit 5.1).

     

    24.1*

     

    Power of Attorney (included on the signature page).

     

    99.1

     

    CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on June 4, 2026).

     

    99.2

     

    Form of Incentive Stock Option Agreement under the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on June 4, 2026).

     

    99.3

     

    Form of Non-Qualified Stock Option Agreement for Company Employees under the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on June 4, 2026).

     

    99.4

     

    Form of Non-Qualified Stock Option Agreement for Non-Employee Directors under CRISPR Therapeutics AG’s 2026 Stock Option and Incentive Plan (incorporated herein by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed on June 4, 2026).

     

    99.5

     

    Form of Restricted Stock Award under the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Registrant’s Current Report on Form 8-K filed on June 4, 2026).

     

    99.6

     

    Form of Restricted Stock Award Agreement for Company Employees under the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan (incorporated herein by reference to Exhibit 10.6 to the Registrant’s Current Report on Form 8-K filed on June 4, 2026).

     


    99.7

     

    Form of Restricted Stock Award Agreement for Non-Employee Directors under the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan (incorporated herein by reference to Exhibit 10.7 to the Registrant’s Current Report on Form 8-K filed on June 4, 2026).

     

     

     

    107*

     

    Filing Fee Table

    *Filed herewith.

    Item 9. Undertakings.

    (a) The registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) herein do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts on June 5, 2026.

    CRISPR THERAPEUTICS AG

    By:

    /s/ Samarth Kulkarni, Ph.D.

    Name: Samarth Kulkarni, Ph.D.

    Title: Chief Executive Officer

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Samarth Kulkarni, Raju Prasad and James R. Kasinger, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on the date indicated below in the capacities indicated:

     

    Signature

    Title

    Date

    /s/ Samarth Kulkarni

     Samarth Kulkarni

    Chief Executive Officer, Chairman and Director

    (principal executive officer)

    June 5, 2026

    /s/ Raju Prasad

     Raju Prasad

    Chief Financial Officer

    (principal financial and accounting officer)

    June 5, 2026

    /s/ Ali Behbahani

     Ali Behbahani

    Director

    June 5, 2026

     

    /s/ Maria Fardis

    Maria Fardis

    Director

    June 5, 2026

     

    /s/ H. Edward Fleming, Jr.

     H. Edward Fleming, Jr.

    Director

    June 5, 2026

     

    /s/ Simeon J. George

      Simeon J. George

    Director

    June 5, 2026

    /s/ John T. Greene

    John T. Greene

    Director

    June 5, 2026

     

    /s/ Katherine A. High

    Katherine A. High

    Director

    June 5, 2026

     

    /s/ Sandesh Mahatme

    Sandesh Mahatme

    Director

    June 5, 2026

     

    /s/ Briggs Morrison

     

    Director

     

    June 5, 2026

    Briggs Morrison

     

     

     

     

     

     

     

    /s/ Christian Rommel

     Christian Rommel

     

    Director

     

    June 5, 2026

     

     

     

     

     

     

    /s/ Douglas A. Treco

     Douglas A. Treco

    Director

    June 5, 2026

     

    /s/ James R. Kasinger

     James R. Kasinger

    Authorized Representative in the United States

    June 5, 2026

     

     


    Get the next $CRSP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRSP

    DatePrice TargetRatingAnalyst
    9/18/2025$70.00Overweight
    Analyst
    2/14/2025$60.00 → $99.00In-line → Outperform
    Evercore ISI
    2/12/2025$35.00Sell → Hold
    TD Cowen
    2/3/2025$65.00Buy
    H.C. Wainwright
    8/6/2024$88.00 → $84.00Buy
    Needham
    8/2/2024$90.00Buy
    Rodman & Renshaw
    6/28/2024Neutral
    Guggenheim
    2/15/2024Peer Perform
    Wolfe Research
    More analyst ratings

    $CRSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by General Counsel and Secretary Kasinger James R.

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    6/2/26 5:42:26 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Medical Officer Patel Naimish

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    6/2/26 5:41:55 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Financial Officer Prasad Raju

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    6/2/26 5:41:26 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CRISPR Therapeutics to Participate in Upcoming Investor Conferences

    ZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. Jefferies Global Healthcare Conference Date: Wednesday, June 3, 2026Time: 9:55 a.m. ET William Blair's 46th Annual Growth Stock ConferenceDate: Wednesday, June 3, 2026Time: 4:40 p.m. CT Goldman Sach's 47th Annual Global Healthcare ConferenceDate: Tuesday, June 9, 2026Time: 2:40 p.m. ET A live webcast will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the

    5/28/26 8:00:00 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach

    Equity Insider News CommentaryIssued on behalf of Avaí Bio, Inc.Joint venture with Austrianova advances the production of cells that produce the longevity protein α-Klotho from encapsulated cells; latest data to be presented at the Second Annual Klotho ConferenceNEW YORK, May 14, 2026 /CNW/ -- Longevity and anti-aging therapeutics have moved decisively from frontier science to organized commercial development through the first half of 2026. Industry data show approximately $3.74 billion of disclosed longevity-biotech financing in Q1 2026 across 49 deals — a 56% increase in capital deployed over Q1 2025 — and the broader longevity biotech market has been forecast to reach approximately US$29.

    5/14/26 9:00:00 AM ET
    $BIOA
    $CRSP
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

    ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced that members of its senior management team will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026 1:40 p.m. PDT. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation. About CRISPR TherapeuticsCRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based m

    5/6/26 8:30:00 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on CRISPR Therapeutics with a new price target

    Analyst initiated coverage of CRISPR Therapeutics with a rating of Overweight and set a new price target of $70.00

    9/18/25 8:39:47 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded CRISPR Therapeutics from In-line to Outperform and set a new price target of $99.00 from $60.00 previously

    2/14/25 8:06:15 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics upgraded by TD Cowen with a new price target

    TD Cowen upgraded CRISPR Therapeutics from Sell to Hold and set a new price target of $35.00

    2/12/25 7:01:19 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Leadership Updates

    Live Leadership Updates

    View All

    CRISPR Therapeutics Proposes New Appointment to the Board of Directors

    ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company's annual general meeting to be held this year. "We are excited to welcome Briggs to our Board of Directors," said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics. "His extensive experience in the pharmaceutical industry and expertise in clinical development will be a tremendous asset as we continue to advance our innovative platform and pip

    1/7/25 8:00:00 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

    -Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wide range of disease areas, including his most recent leadership role as the Global Development Therapeutic Area Head of Immunology and Inflammation at Sanofi. In addition, the Company al

    5/23/24 8:00:00 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics Announces Transition of Chief Financial Officer

    ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the hiring and appointment of Raju Prasad, Ph.D., as Chief Financial Officer, effective March 14, 2023. He joins CRISPR Therapeutics from William Blair & Company, where he served as a Partner and Senior Equity Research Analyst covering cell therapy, gene therapy, and gene editing companies. Dr. Prasad succeeds Brendan Smith, who is leaving the Company to pursue external opportunities. "I'm excited to welcome Raju to our leadership team," said Samarth Kulkarni, Ph.D., Chief Exec

    3/13/23 4:15:00 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CRISPR Therapeutics AG

    SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

    12/10/24 1:34:45 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by CRISPR Therapeutics AG (Amendment)

    SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

    4/10/24 11:58:51 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by CRISPR Therapeutics AG (Amendment)

    SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

    2/12/24 6:22:35 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Patel Naimish bought $49,704 worth of shares (1,508 units at $32.96) (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    1/27/26 5:35:15 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Treco Douglas A bought $1,140,600 worth of shares (20,000 units at $57.03), increasing direct ownership by 1,000% to 22,000 units (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    8/8/25 4:06:28 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director George Simeon bought $51,499,918 worth of shares (989,812 units at $52.03) (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    7/17/25 5:19:13 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    SEC Filings

    View All

    SEC Form S-8 filed by CRISPR Therapeutics AG

    S-8 - CRISPR Therapeutics AG (0001674416) (Filer)

    6/5/26 8:15:06 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics AG filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - CRISPR Therapeutics AG (0001674416) (Filer)

    6/4/26 4:45:20 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CRISPR Therapeutics AG

    SCHEDULE 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

    5/15/26 12:59:25 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Financials

    Live finance-specific insights

    View All

    CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies

    -58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis- -Durable responses in LBCL achieved with six-month CR rate of 21% and longest response on-going at over 18 months after initial infusion- -Response rates and durability are similar to approved autologous CD19 CAR-T therapies on an ITT basis- -Positively differentiated safety profile; no Grade 3 or higher cytokine release syndrome (CRS) and low rates of infection and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)- -Expanding CARBON into a potentially registrational trial in 1Q 20

    10/12/21 4:01:00 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data

    -Management to host conference call and webcast on October 12th at 4:30 p.m. ET- ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that management will host a virtual event on October 12, 2021 at 4:30 p.m. ET to highlight clinical data from its ongoing Phase 1 CARBON trial assessing the safety and efficacy of CTX110, its wholly-owned allogeneic chimeric antigen receptor T cell (CAR-T) investigational therapy targeting CD19, for the treatment of relapsed or refractory B-cell malignancies. Conference Call and Web

    10/5/21 4:05:00 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care